Neurocrine Biosciences Inc (NAS:NBIX)
$ 140.555 -1.445 (-1.02%) Market Cap: 14.15 Bil Enterprise Value: 13.60 Bil PE Ratio: 38.72 PB Ratio: 5.93 GF Score: 89/100

Neurocrine Biosciences Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 07:30PM GMT
Release Date Price: $93.59 (-0.14%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much. Good afternoon, everybody. It's my pleasure to be hosting Eiry Roberts, Chief Medical Officer at Neurocrine; and Kyle Gano, Chief Business Development Officer. I think we're going to use this as an opportunity to really kind of dive deeper into some of these pipeline assets and preview some of the data that's coming up.

Questions & Answers

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Maybe to kick things off, maybe, Eiry, I think it'd be interesting if you just give a quick sort of high-level overview of the status of each pipeline program. And then Kyle, maybe you could sort of follow with some just sort of thought strategically on Neurocrine and the types of transactions you've been doing, and as the company matures, if maybe the types of transactions you might be willing to do either from a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot